Akadeum Life Sciences Inc. hopes to transform the world of cell therapy with the Alerion cell separation system, which it plans to launch in the next 12 months, Brandon McNaughton, founder and CEO of Akadeum, told BioWorld. The instrument will provide a closed system for separating T cells from a leukopak using Akadeum’s buoyancy-activated cell-sorting (BACS) microbubble technology.
Human natural killer (NK) cells play an essential role in tumor surveillance and can attack malignant cells in an antigen-independent manner. Because of this, allogeneic NK cells can be engineered as off-the-shelf therapies and may be used to target different hematological malignancies or solid tumors.
In 2022, neuroscience research made significant advances by understanding the role of large-scale neuronal connections in disorders. So did cancer research.
In 2022, neuroscience research made significant advances by understanding the role of large-scale neuronal connections in disorders. So did cancer research.
JW Therapeutics Co. Ltd. has formed a partnership with 2seventy Bio Inc. to launch a translational and clinical cell therapy development program for the development of T cell-based immunotherapies in mainland China, Hong Kong and Macao.
JW Therapeutics Co. Ltd. has formed a partnership with 2seventy Bio Inc. to launch a translational and clinical cell therapy development program for the development of T cell-based immunotherapies in mainland China, Hong Kong and Macao.
Akadeum Life Sciences Inc. is rolling out a new dead cell removal kit using its patented microbubble technology. The research-use-only Dead Cell Removal Microbubble Kit (DCR kit) is currently available via direct sales to the U.S. market and on the company’s website. Akadeum’s DCR kit is designed to resolve current challenges in dead cell removal, which can hamper elimination of dead cells and the salvage of viable ones for research use.
Australia’s Therapeutic Goods Administration (TGA) should better align its definitions and classifications for gene, cell and tissue frameworks with international regulators, stakeholders said.
Australia’s Therapeutic Goods Administration (TGA) should better align its definitions and classifications for gene, cell and tissue frameworks with international regulators, stakeholders said.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
